Home / Combinations / CJC-1295 + Ipamorelin + GHRP-6
CombinationMuscle GrowthFat LossRecoveryAnecdotal evidence
CJC-1295 + Ipamorelin + GHRP-6
GH Secretagogue Max
An advanced triple-secretagogue stack designed to maximally stimulate endogenous GH release through three complementary mechanisms. CJC-1295 extends GHRH signalling, Ipamorelin provides selective ghrelin-receptor stimulation with a clean side-effect profile, and GHRP-6 adds additional pulse amplitude alongside appetite stimulation. This combination is popular in performance communities seeking the highest attainable GH output without exogenous HGH.
Stack components
CJC-1295 (without DAC)Compound 01
IpamorelinCompound 02
GHRP-6Compound 03
3
Compounds
3
Sources on file
15
Providers carry all
Mechanism
What each compound is researched for on its own. Nothing here describes an interaction between them.
Compound 01
CJC-1295 (without DAC)
Provides the sustained GHRH signal backbone of the stack, setting the hormonal stage for the additional secretagogues to stack upon by extending baseline GH pulse duration.
Compound 02
Ipamorelin
Adds selective ghrelin-receptor stimulation with a minimal side-effect profile, contributing to GH pulse amplitude without introducing meaningful cortisol or prolactin elevation.
Compound 03
GHRP-6
Contributes additional GH pulse amplitude and appetite stimulation via ghrelin signalling, aimed at maximising total GH output; the appetite side effect can be a deliberate tool during caloric surplus phases.
Composition
3 compounds · 3 research areas
Stated as recorded. This page describes each compound separately and makes no claim that they act together.
Safety notes
All three are unapproved research compounds. GHRP-6 commonly causes significant appetite stimulation and transient cortisol and prolactin elevation, distinguishing it from the cleaner side-effect profile of Ipamorelin. Risks overlap with chronically elevated GH: water retention, joint discomfort, and potential insulin resistance. Contraindicated in active or hormone-sensitive malignancies; no formal safety data exists for this triple combination.
Author-written. Not derived from any compound field, and not covered by the profile-integrity audit that gates the peptide pages.
Research references3 sources
Moderate
Prolonged stimulation of GH and IGF-I secretion by CJC-1295
J Clin Endocrinol Metab 2006
PeptideBase notePer-component source only — no combination study exists
Moderate
Ipamorelin, the first selective growth hormone secretagogue
Eur J Endocrinol 1998
PeptideBase notePer-component source only — no combination study exists
Weak
On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone
Endocrinology 1984
PeptideBase noteFoundational discovery paper — no combination study exists
Related combinations3 share an area
Educational use only
PeptideBase documents what compounds are researched together and what evidence exists for each one separately. It does not provide medical advice, diagnosis, treatment, prescribing guidance or dosing instructions. Last reviewed 19 Apr 2026.
PeptideBase documents what compounds are researched together and what evidence exists for each one separately. It does not provide medical advice, diagnosis, treatment, prescribing guidance or dosing instructions. Last reviewed 19 Apr 2026.